Citations

Showing 10 of 108152 citations.

Lung Cancer Risk among Patients with Asthma–Chronic Obstructive Pulmonary Disease Overlap
Charokopos, Antonios , Braman, Sidney S. , Brown, Stacey A. Whittaker, Mhango, Grace, Zulueta, Javier J. , Sharma, Sunita , Holguín, Fernando , Federman, Alex D. , Wisnivesky, Juan P. , Zulueta, Javier J , Sigel, Keith M, Brown, Stacey-Ann Whittaker , de-Torres, Juan Pablo , Sigel, Keith Magnus , Powell, Charles Arthur

Mayo Clinic

Annals of the American Thoracic Society | May 21, 2021 | Volume: 18 | Issue: 11 | Pages: 1894-1900

10.1513/annalsats.202010-1280oc | PMID 34019783 Get It

Abstract Rationale Chronic obstructive pulmonary disease (COPD) is a well-established independent risk factor for lung cancer; however, the literature on the association between asthma and lung cancer is mixed. Whether asthma–COPD overlap (ACO) is associated with lung cancer has not been studied. Objectives We aimed to compare lung cancer risk among patients with ACO versus COPD and other conditions associated with airway obstruction. Methods We studied 13,939 smokers from the National Lung Cancer Screening Trial who had baseline spirometry and used spirometric indices and history of childhood asthma to categorize participants into five specific airway disease subgroups. We used Poisson regression to compare unadjusted and adjusted lung cancer risk. Results The incidence rate of lung cancer per 1,000 person-years was as follows: ACO, 13.2 (95% confidence interval [CI], 8.1–21.5); COPD, 11.7 (95% CI, 10.5–13.1); asthmatic smokers, 1.8 (95% CI, 0.6–5.4); Global Initiative for Chronic Obstructive Lung Disease–Unclassified, 7.7 (95% CI, 6.4–9.2); and normal spirometry smokers, 4.1 (95% CI, 3.5–4.8). Patients with ACO had increased adjusted risk of lung cancer compared with patients with asthma (incidence rate ratio [IRR], 4.5; 95% CI, 1.3–15.8) and normal spirometry smokers (IRR, 2.3; 95% CI, 1.3–4.2) in models adjusting for other risk factors. Adjusted lung cancer incidence in patients with ACO and COPD were not found to be different (IRR, 1.2; 95% CI, 0.7–2.1). Conclusions The risk of lung cancer among patients with ACO is similar to those with COPD and higher than other groups of smokers. These results provide further evidence that COPD, with or without a history of childhood asthma, is an independent risk factor for lung cancer.
Modified Chondrocutaneous Flaps for Middle Helical Rim Defects
Lawson, Abby, Geisler, Emily L. , Leach, Garrison A., Granger, Peter , Holcombe, Travis C.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 21, 2021 | Volume: 9 | Issue: 5 | Pages: e3592

10.1097/gox.0000000000003592 | PMID 34036028 Get It

SUMMARY This article describes a unique approach for reconstruction of large helical rim defects. By raising bilateral chondrocutaneous flaps of the helical rim while including a semicircular chondrocutaneous excision of the adjacent scapha and antihelix, large defects can be repaired with minimal loss to the overall external ear circumference. This is a technically simple and reliable method that has resulted in excellent cosmetic outcomes and minimal morbidity in our practice.
Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment
Abraham, Neena S. , Inselman, Jonathan , Shah, Nilay D. , Yao, Xiaoxi , Herrin, Jeph , Noseworthy, Peter A. , Ngufor, Che

Mayo Clinic

JAMA Network Open | May 21, 2021 | Volume: 4 | Issue: 5 | Pages: e2110703

10.1001/jamanetworkopen.2021.10703 | PMID 34019087 Get It

Thrombolysis for COVID-19-associated bioprosthetic mitral valve thrombosis with shock
Vinnakota, Shravya , Jentzer, Jacob C. , Luis, Sushil A , Jentzer, Jacob C , Luis, Sushil Allen

Mayo Clinic

European Heart Journal | May 21, 2021 | Volume: 42 | Issue: 39 | Pages: 4093-4093

10.1093/eurheartj/ehab333 | PMID 34115844 Get It

Arthroplasty in the hand: what works and what doesn’t?
Ishikawa, Hajime , Rizzo, Marco , Solomons, Michael, Herren, Daniel B. , Ross, Mark

Mayo Clinic

Journal of Hand Surgery (European Volume) | May 21, 2021 | Volume: 47 | Issue: 1 | Pages: 4-11

10.1177/17531934211017703 | PMID 34018871 Get It

This review describes the different possibilities for arthroplasties at the proximal interphalangeal joint, thumb carpometacarpal joint, distal radioulnar joint, metacarpophalangeal joint and the wrist. For each joint, the indication for arthroplasty is explained, the surgical technique with the suitable implant is described and a brief summary of the outcomes reported in the literature is given.
Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes
Fisher, Deborah A. , Saoud, Leila, Karlitz, Jordan J. , Fisher, Deborah A , Limburg, Paul J. , Fendrick, A. Mark , Ozbay, A. Burak

Mayo Clinic

Cancer Prevention Research | May 21, 2021 | Volume: 14 | Issue: 9 | Pages: 845-850

10.1158/1940-6207.capr-21-0075 | PMID 34021023 Get It

Abstract Colorectal cancer–screening models commonly assume 100% adherence, which is inconsistent with real-world experience. The influence of adherence to initial stool-based screening [fecal immunochemical test (FIT), multitarget stool DNA (mt-sDNA)] and follow-up colonoscopy (after a positive stool test) on colorectal cancer outcomes was modeled using the Colorectal Cancer and Adenoma Incidence and Mortality Microsimulation Model. Average-risk individuals without diagnosed colorectal cancer at age 40 undergoing annual FIT or triennial mt-sDNA screening from ages 50 to 75 were simulated. Primary analyses incorporated published mt-sDNA (71%) or FIT (43%) screening adherence, with follow-up colonoscopy adherence ranging from 40% to 100%. Secondary analyses simulated 100% adherence for stool-based screening and colonoscopy follow-up (S1), published adherence for stool-based screening with 100% adherence to colonoscopy follow-up (S2), and published adherence for both stool-based screening and colonoscopy follow-up after positive mt-sDNA (73%) or FIT (47%; S3). Outcomes were life-years gained (LYG) and colorectal cancer incidence and mortality reductions (per 1,000 individuals) versus no screening. Adherence to colonoscopy follow-up after FIT had to be 4%–13% higher than mt-sDNA to reach equivalent LYG. The theoretical S1 favored FIT versus mt-sDNA (LYG 316 vs. 297; colorectal cancer incidence reduction 68% vs. 64%; colorectal cancer mortality reduction 76% vs. 72%). The more realistic S2 and S3 favored mt-sDNA versus FIT (S2: LYG 284 vs. 245, colorectal cancer incidence reduction 61% vs. 50%, colorectal cancer mortality reduction 69% vs. 59%; S3: LYG 203 vs. 113, colorectal cancer incidence reduction 43% vs. 23%, colorectal cancer mortality reduction 49% vs. 27%, respectively). Incorporating realistic adherence rates for colorectal cancer screening influences modeled outcomes and should be considered when assessing comparative effectiveness. Prevention Relevance: Adherence rates for initial colorectal cancer screening by FIT or mt-sDNA and for colonoscopy follow-up of a positive initial test influence the comparative effectiveness of these screening strategies. Using adherence rates based on published data for stool-based testing and colonoscopy follow-up yielded superior outcomes with an mt-sDNA versus FIT-screening strategy.
Identifying patients at risk for nonroutine discharge after surgery for cervical myelopathy: an analysis from the Quality Outcomes Database
Mummaneni, Praveen V. , Bydon, Mohamad , Knightly, John J. , Alvi, Mohammed Ali , Yolcu, Yagiz U. , Chan, Andrew K. , Foley, Kevin T. , Slotkin, Jonathan R., Potts, Eric A. , Shaffrey, Mark E., Shaffrey, Christopher I. , Fu, Kai-Ming, Wang, Michael Y. , Park, Paul , Upadhyaya, Cheerag D., Asher, Anthony L. , Tumialán, Luis M. , Bisson, Erica F. , Alvi, Mohammed Ali

Mayo Clinic

Journal of Neurosurgery: Spine | May 21, 2021 | Volume: 35 | Issue: 1 | Pages: 25-33

10.3171/2020.11.spine201442 | PMID 33962388 Get It

OBJECTIVE Optimizing patient discharge after surgery has been shown to impact patient recovery and hospital/physician workflow and to reduce healthcare costs. In the current study, the authors sought to identify risk factors for nonroutine discharge after surgery for cervical myelopathy by using a national spine registry. METHODS The Quality Outcomes Database cervical module was queried for patients who had undergone surgery for cervical myelopathy between 2016 and 2018. Nonroutine discharge was defined as discharge to postacute care (rehabilitation), nonacute care, or another acute care hospital. A multivariable logistic regression predictive model was created using an array of demographic, clinical, operative, and patient-reported outcome characteristics. RESULTS Of the 1114 patients identified, 11.2% (n = 125) had a nonroutine discharge. On univariate analysis, patients with a nonroutine discharge were more likely to be older (age ≥ 65 years, 70.4% vs 35.8%, p < 0.001), African American (24.8% vs 13.9%, p = 0.007), and on Medicare (75.2% vs 35.1%, p < 0.001). Among the patients younger than 65 years of age, those who had a nonroutine discharge were more likely to be unemployed (70.3% vs 36.9%, p < 0.001). Overall, patients with a nonroutine discharge were more likely to present with a motor deficit (73.6% vs 58.7%, p = 0.001) and more likely to have nonindependent ambulation (50.4% vs 14.0%, p < 0.001) at presentation. On multivariable logistic regression, factors associated with higher odds of a nonroutine discharge included African American race (vs White, OR 2.76, 95% CI 1.38–5.51, p = 0.004), Medicare coverage (vs private insurance, OR 2.14, 95% CI 1.00–4.65, p = 0.04), nonindependent ambulation at presentation (OR 2.17, 95% CI 1.17–4.02, p = 0.01), baseline modified Japanese Orthopaedic Association severe myelopathy score (0–11 vs moderate 12–14, OR 2, 95% CI 1.07–3.73, p = 0.01), and posterior surgical approach (OR 11.6, 95% CI 2.12–48, p = 0.004). Factors associated with lower odds of a nonroutine discharge included fewer operated levels (1 vs 2–3 levels, OR 0.3, 95% CI 0.1–0.96, p = 0.009) and a higher quality of life at baseline (EQ-5D score, OR 0.43, 95% CI 0.25–0.73, p = 0.001). On predictor importance analysis, baseline quality of life (EQ-5D score) was identified as the most important predictor (Wald χ2 = 9.8, p = 0.001) of a nonroutine discharge; however, after grouping variables into distinct categories, socioeconomic and demographic characteristics (age, race, gender, insurance status, employment status) were identified as the most significant drivers of nonroutine discharge (28.4% of total predictor importance). CONCLUSIONS The study results indicate that socioeconomic and demographic characteristics including age, race, gender, insurance, and employment may be the most significant drivers of a nonroutine discharge after surgery for cervical myelopathy.
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology
Apostolova, Liana G. , Aisen, Paul , Eloyan, Ani , Fagan, Anne M. , Fargo, Keith N. , Gatsonis, Constantine , Grinberg, Lea T. , Jack, Clifford R. , Kramer, Joel H. , Kukull, Walter A. , Murray, Melissa E. , Nudelman, Kelly , Rumbaugh, Malia, Vemuri, Prashanthi , Trullinger, Amy, Iaccarino, Leonardo , Day, Gregory S. , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Rogalskı, Emily , Salloway, Steve , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Jack, Clifford R , Vemuri, Prashanthi , Day, Gregory S , Murray, Melissa E , Grinberg, Lea , Rabinovici, Gil D , Nudelman, Kelly N , Wingo, Thomas S , Foroud, Tatiana , Koeppe, Robert A. , Toga, Arthur W. , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | May 21, 2021 | Volume: 17 | Issue: 12 | Pages: 2043-2055

10.1002/alz.12350 | PMID 34018654 Get It

AbstractPatients with early‐onset Alzheimer's disease (EOAD) are commonly excluded from large‐scale observational and therapeutic studies due to their young age, atypical presentation, or absence of pathogenic mutations. The goals of the Longitudinal EOAD Study (LEADS) are to (1) define the clinical, imaging, and fluid biomarker characteristics of EOAD; (2) develop sensitive cognitive and biomarker measures for future clinical and research use; and (3) establish a trial‐ready network. LEADS will follow 400 amyloid beta (Aβ)‐positive EOAD, 200 Aβ‐negative EOnonAD that meet National Institute on Aging–Alzheimer's Association (NIA‐AA) criteria for mild cognitive impairment (MCI) or AD dementia, and 100 age‐matched controls. Participants will undergo clinical and cognitive assessments, magnetic resonance imaging (MRI), [18F]Florbetaben and [18F]Flortaucipir positron emission tomography (PET), lumbar puncture, and blood draw for DNA, RNA, plasma, serum and peripheral blood mononuclear cells, and post‐mortem assessment. To develop more effective AD treatments, scientists need to understand the genetic, biological, and clinical processes involved in EOAD. LEADS will develop a public resource that will enable future planning and implementation of EOAD clinical trials.
The Agility Total Ankle Arthroplasty: A Concise Follow-up at a Minimum of 20 Years
Saltzman, Charles L. , Hartog, Taylor Den , Carlson, Samuel W. , Callaghan, John J. , Alvine, Greg , Alvine, Frank , Den Hartog, Taylor , Carlson, Samuel, Bedard, Nicholas A.

Mayo Clinic

Foot & Ankle International | May 21, 2021 | Volume: 42 | Issue: 10 | Pages: 1241-1244

10.1177/10711007211010179 | PMID 34018424 Get It

Background: Between 1984 and 1994, a single surgeon performed 132 primary cementless total ankle replacements using the Agility total arthroplasty system. The purpose of this study was to report on the 20-year follow-up, which we believe is the first study with this length of follow-up. Methods: Living patients were contacted and interviewed to determine the status of their implant (revised or unrevised) and to answer a simple questionnaire concerning overall satisfaction, pain, and functional improvement, as in a previous study. Thirty-three (26.2%) patients with 33 (25%) ankles of the original series were alive at a minimum of 20 years postoperatively, with a median follow-up of 22 years. They were asked to return to the office for standing anteroposterior and lateral ankle and foot radiographs or to send these radiographs if performed elsewhere. Radiographs were evaluated for radiolucencies around the components and subsidence (talar component) or migration (tibial component) of components. Results: Seventeen (13.5%) ankles of the 126 available for follow-up, including 5 (15.2%) ankles in living patients, had undergone revision ( n = 10) or arthrodesis ( n = 7) for loosening. One additional ankle was revised for infection and 1 for talar component malposition; thus, 19 (15.1%) ankles were revised. Conclusion: These results should provide a 20-year benchmark for newer total ankle arthroplasty designs when a similar length of follow-up becomes available. Level of Evidence: Level III, retrospective cohort study.
Chronic Anticholinergic Toxicity Discovered in a Pharmacogenomics, Polypharmacy Patient
Schuh, Michael J. , Crosby, Sheena

Mayo Clinic

The Senior Care Pharmacist | May 21, 2021 | Volume: 36 | Issue: 6 | Pages: 304-310

10.4140/tcp.n.2021.304 | PMID 34016227 Get It

Objective: To report a case of chronic anticholinergic toxicity in a referred, pharmacogenomics (PGx), polypharmacy patient. Summary: The patient is a 67-year-old male who was referred to the polypharmacy service for a PGx consult. This patient has had episodic fever of unknown origin, general cutaneous vasodilation, tremors, jerks, and brain fogginess which have been unexplained. He has seen specialists from infectious disease, rheumatology, endocrinology, and neurology with no contributory condition causing these symptoms, so he was referred for PGx testing and evaluation by the polypharmacy pharmacist. Conclusion: This case demonstrates the importance of pharmacist-patient consultations and how a PGx consult may expose polypharmacy medication-related problems of greater significance than the PGx indication for the consult. In addition, the case demonstrates positive interprofessional collaboration between pharmacists and physicians to more effectively solve complex medication-related problems that may not be easily diagnosed through objective lab or diagnostic testing.